DNA methylation · curated MDI catalog

DNA methylation cancer tests

DNA methylation patterns can provide molecular information about cell state and cancer biology. MDI keeps performance attached to the assay version, population and study that produced it.

18 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • Avantect Ovarian Cancer Test — Cell-free DNA blood LDT intended as an aid to earlier ovarian-cancer detection in women at elevated risk.
  • Avantect Pancreatic Cancer Test — Blood-based multi-analyte, multiomic test intended to support earlier pancreatic cancer detection in elevated-risk patients.
  • Cancerguard — Multi-cancer early detection laboratory-developed test for adults 50–84; breast/prostate screening and precancer detection are outside the documented current use.
  • Cologuard — Stool-based colorectal cancer screening test for average-risk adults.
  • Cologuard Plus — Prescription multitarget stool-based colorectal cancer screening test for average-risk adults age 45 years or older.
  • ColoHealth — Blood-based methylated SEPT9 colorectal cancer testing family; current ColoHealth Direct LDT and historical FDA device lineage are modeled separately.
  • Confirm mdx — PCR-based DNA methylation test performed on prior negative prostate-biopsy tissue to estimate the likelihood of occult clinically significant prostate cancer and inform repeat-biopsy decisions.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • Galleri — Prescription-only multi-cancer early detection test.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Guardant360 Tissue — Tissue-based multiomic comprehensive profiling for advanced solid tumors.
  • Northstar Response — Tissue-free methylated-ctDNA liquid biopsy for quantitative treatment-response monitoring across advanced solid tumors.
  • OverC Multi-Cancer Detection — Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
  • Shield — Blood-based colorectal cancer screening test.
  • SimpleScreen CRC — FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older.
  • SimpleScreen Lung — Blood-based multiomic LDT intended to increase lung-cancer screening participation among eligible high-risk adults not completing LDCT.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • Tempus xM — Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance